Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
Tongji University · Harbin Medical University · +36 more institutions
Abstract
Amivantamab has been approved for the treatment of patients with advanced non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertions who have had disease progression during or after platinum-based chemotherapy. Phase 1 data showed the safety and antitumor activity of amivantamab plus carboplatin–pemetrexed (chemotherapy). Additional data on this combination therapy are needed. Download a PDF of the Research Summary. In this phase 3, international, randomized trial, we assigned in a 1:1 ratio patients with advanced NSCLC with EGFR exon 20 insertions who had not received previous systemic therapy to receive intravenous amivantamab plus chemotherapy…
Citation impact
- FWCI
- 81.03
- Percentile
- 100%
- References
- 30
Authors
28- CZCaicun ZhouCorresponding
Tongji University, Harbin Medical University, Shanghai Pulmonary Hospital, First Affiliated Hospital of Harbin Medical University
- KTKejing Tang
Harbin Medical University, Sun Yat-sen University, The First Affiliated Hospital, Sun Yat-sen University, First Affiliated Hospital of Harbin Medical University
- BCByoung Chul Cho
Harbin Medical University, Yonsei University, First Affiliated Hospital of Harbin Medical University
- BLBaogang Liu
Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Harbin Medical University
- LPLuis Paz‐Ares
Harbin Medical University, Hospital Universitario 12 De Octubre, First Affiliated Hospital of Harbin Medical University
Topics & keywords
- Epidermal growth factor receptor
- Lung cancer
- Exon
- Medicine
- Chemotherapy
- Oncology
- Internal medicine
- Cancer research
- Good health and well-being